Presentation is loading. Please wait.

Presentation is loading. Please wait.

GE Healthcare AS Medical Diagnostics Norway

Similar presentations


Presentation on theme: "GE Healthcare AS Medical Diagnostics Norway"— Presentation transcript:

1 GE Healthcare AS Medical Diagnostics Norway
Who are we today? What are our success criteria?

2 Who we are: GE business segments
Aviation Energy Enterprise Solutions Water Oil & Gas Commercial Finance GE Money Corporate Treasury Transportation Healthcare Technology Infrastructure GE Capital NBC Universal GE is Imagination at Work - a diversified technology, media and financial services company focused on solving some of the world's toughest problems. With products and services ranging from aircraft engines, power generation, water processing and security technology to medical imaging, business and consumer financing, media content and industrial products, we serve customers in more than 100 countries and employ more than 320,000 people worldwide. GE Commercial Finance Loans, operating leases, financing programs, commercial insurance, and an array of other products and services aimed at enabling business worldwide to grow. GE Money A leading provider, under the GE Money brand, of credit services to consumers, retailers and automotive dealers around the world. GE Healthcare Helping healthcare professionals world-wide, transform patient care through products and services designed to help predict, diagnose, access information and treat disease earlier and more effectively. GE Industrial Providing a broad range of products and services throughout the world, including appliances and lighting; plastics and silicones products; and equipment services. GE Infrastructure One of the world's leading providers of aviation, energy, oil and gas, rail and water process technologies. NBC Universal One of the world's leading media and entertainment companies in the development, production and marketing of entertainment, news and information to a global audience               

3 Broad solutions for healthcare
Medical Diagnostics Electronic medical records Diagnostic imaging & Surgery Discovery tools Integrated admin. & clinical Clinical Systems Picture Archiving System (PACS) Protein & cell sciences Clinical tissue biomarkers Broad-based Diagnostics Life Sciences Information Technology GE’s product offerings go deep and wide. From Diagnostic imaging products across the standard modalities and new emerging modalities like Molecular Imaging, to interventional, surgical guidance, bio pharmaceutical production and integrated IT solutions

4 GE Healthcare $17B global business unit of GE
$1B+/year in R&D investment Over 2,000 research scientists Nearly 1,000 PhDs Multiple disciplines 45 different nationalities employees GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest. GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $15 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 44,000 people committed to serving healthcare professionals and their patients in more than 100 countries. There’s more information about GE Healthcare on our website at

5 Medical Diagnostics (~4500 employees)
The only Pharmaceutical unit in GE World leader in contrast agents and nuclear medicine products for diagnostic imaging across all modalities.

6 GE Healthcare AS – Norwegian branch of Medical Diagnostics Milestones
Pharmacist Morten Nyegaard Founder of Nyegaard & Co, later Nycomed, in 1874 Nycomed’s first X-ray contrast medium, a copy prep. reg.1934 Nycomed develops world’s first non-ionic X-ray contrast medium in collaboration with Professor Torsten Almén of Lund, Sweden Omnipaque, 2nd generation non-ionic X-ray contrast medium, for many years ranked among the top 10 pharma- ceutical products sold world-wide. The exceptional R&D environment that has emerged in Norway since will continue to play an important role in the development of new products for diagnosis, treatment and prevention of disease. This position was continued with the merger between Nycomed and Amersham International in further strengthened under GE Healthcare from 2004

7 GE Healthcare AS Lindesnes site Oslo site
(Primary manuf. 350 employees) Oslo site (Sec. manuf., R&D, 650 employees) Total revenues (incl exports): $ 1,0 billion In market sales: $15,5 million R&D 55 $ (ex 5.11) 136’ $ (08’) ( approx. 1 mill $ 09’) approx. 200 employees GEHC total no of employees: Largest Pharma player in Norway

8 Key promoted brands >500m >700m >300m >180m >40m
Product Description ~ Annual Rev $m Launched 1993 ONLY Iso-Osmolar media All disease areas >500m Launched 1982 Global Gold standard All disease areas >700m Launched 1996 Myocardial perfusion >300m Launched 1993 Non-ionic MRI All disease areas >180m Launched 2000 First agent to identify Parkinson’s Disease >40m

9 So what’s makes a success? (I)
Key competences – focus Decisiveness (privately owned at the time) Available funding The right product area – niche(?) The right product opportunity - IPR Key competence - develop

10 So what’s makes a success? (II)
Right strategy (build from strength) Leverage partnerships (Schering/Daiichi/Sterling) & local strength Transition to own presence (Schering-Sterling) Focus on core competencies (CM…) Continuous improvements (Lindesnes/primary production – retain competitiveness) Long term R&D strategy and continuous investments (build capacity + feed pipeline) Business Dvlp – M&A X

11 Predict & Prevent Disease …
The Future … Molecular Medicine Molecular Therapeutics Molecular Imaging Molecular Diagnostics Predict Gene Assay Molecular Diagnostics Pinpoint Imaging Imaging, IVD Track and Verify Molecular Imaging Prevent/Treat Molecular Therapeutics Detect Protein In Vitro (IVD) Let me try and give you an example in Alzheimer disease: Affects 4 million people, cost $10B not to mention the impact on the families of those afflicted. Let’s walk through the model Predict - Gene assays, genetic predisposition Detect - exposing disease before the symptoms present … Protein expression Pinpoint - Immediately you want where is it and how much? Personalize - understanding your disease dictates the treatment, not the average. Treat - there are new types of treatments being developed to interrupt the pathway of disease … Track - lastly you want to know in days not months if the treatment is working … back to imaging or Imaging and Diagnostics that will: assess risk earlier to intervene with preventive measures diagnose earlier to intervene and stop chronic disease in its tracks Diagnose more specifically and understand the patient better to select the right therapy Deliver therapy, Monitor therapy delivery, and follow-up to measure efficacy

12 Molecular Medicine Diagnose and treat before symptoms appear
Provide treatments tailored to individual’s genetic makeup Focusing on cancer, heart disease and Alzheimer's Collaborating with leading pharmaceutical companies and medical researchers GE in best position to grow and leverage Imagine that a life-threatening disease is detected before symptoms appear, therapeutic drugs are seen hitting their target instantaneously, therapeutic efficacy is measured in hours instead of months, or life-saving drugs tailored to your genetic make-up and disease variant get to market years faster than possible today. This is the promise of molecular imaging. Through research being done on nuclear medicine, PET, and MR systems, to name a few, GE Global Research Center researchers -- in partnership with several pharmaceutical companies and GE Healthcare customers & clinicans -- will soon discover how diagnosis and treatment decisions can be made at the cellular level. Through genomic information from the Human Genome Project, doctors eventually will know a person's predisposition for disease, identify markers of early, aggressive disease, and prescribe a therapy targeted to prevent it years before symptoms even occur. GE Healthcare is now playing a key role in pre-clinical molecular medicine research and paving the road to the promise of molecular imaging with our exclusive eXplore series micro imaging systems for in vitro and in vivo scanning. The eXplore series use rapid, full-volume imaging acquisition geometries to maximize scanning efficiency and provide isotropic resolution of in vitro and in vivo studies with minimal dose. eXplore applications include vascular and bone imaging, angiogenesis, phenotyping and anatomical registration of molecular imaging data.

13 Portfolio spans modalities and diseases
Contrast Media Molecular Imaging Anatomy Function Perfusion Viability Metabolism X-Ray/CT MRI Optical Imaging SPECT Targeted SPECT PET Cardiology Oncology Neurology Urology

14 Post GE – why Norway? Focus on core competencies (CM + MI) feed product pipeline Continuous improvements (Lindesnes/primary production – maintain competitiveness) Available competence – limitations Norway Available funding  need competitive environment (R&D/technology developments: incentives) – global competition Norway need to stay competitive – do’s & don’ts: Cost levels  invest in high tech/focus on cost drivers Funding  develop incentives – establish competitive advantages – commercialization is key Competence  education + “brain” import simplification Do not create obstacles  harmonized rules & regulations

15 Takk! Spørsmål?

16 *Includes costs of failed compounds
What is Pharma? Therapeutics Diagnostics $650B global market $500MM - $1B sales per year Highly regulated industry from development through marketing General patent life ~ 20 yrs Average drug development 10 – 15 yrs at a cost of greater than $1B* Generally thought of as encompassing therapeutic drugs, both branded and generic Chronic administration $7B global market Sub-segment of the pharmaceutical industry (“specialty pharma”) $50 - $200MM sales per year Drugs used to aid in diagnostic imaging procedures that highlight organs, tissues and processes in the body Acute administration Only 2 products approved in past 10 years POS ranges from 16% phase 1 to 50% phase 3 *Includes costs of failed compounds

17 Fra Nyegaard & Co til GE Healthcare
Morten Nyegaard, cand pharm Nyegaard & Co (Nyco) 1986 Nycomed AS 1992 Nycomed Imaging AS 1997 Nycomed Amersham Imaging AS Amersham Health AS 2004 GE Healthcare


Download ppt "GE Healthcare AS Medical Diagnostics Norway"

Similar presentations


Ads by Google